Objective-Experimental evidence supports an antineoplastic activity of marine omega-3 polyunsaturated fatty acids (ω-3 PUFAs; including eicosapentaenoic acid, docosahexaenoic acid, and docosapentaenoic acid). However, the influence of ω-3 PUFAs on colorectal cancer (CRC) survival is unknown.
AUTHOR CONTRIBUTIONSDrs Song and Chan have full access to all of the data in the study, and take responsibility for the integrity of the data and the accuracy of the data analysis.
HHS Public AccessAuthor manuscript Gut. Author manuscript; available in PMC 2017 October 01.
Author Manuscript Author ManuscriptAuthor Manuscript
Author ManuscriptDesign-Within the Nurses' Health Study and Health Professionals Follow-up Study, we prospectively studied CRC-specific and overall mortality in a cohort of 1,659 CRC patients according to intake of marine ω-3 PUFAs and its change after diagnosis.Results-Higher intake of marine ω-3 PUFAs after CRC diagnosis was associated with lower risk of CRC-specific mortality (P for trend=0.03). Compared with patients who consumed less than 0.10 g/day of marine ω-3 PUFAs, those consuming at least 0.30 g/day had an adjusted hazard ratio for CRC-specific mortality of 0.59 (95% confidence interval [CI], 0.35 to 1.01). Patients who increased their marine ω-3 PUFA intake by at least 0.15 g/day after diagnosis had a hazard ratio of 0.30 (95% CI, 0.14 to 0.64, P for trend<0.001) for CRC deaths, compared with those who did not change or changed their intake by less than 0.02 g/day. No association was found between postdiagnostic marine ω-3 PUFA intake and all-cause mortality (P for trend=0.47).Conclusion-High marine ω-3 PUFA intake after CRC diagnosis is associated with lower risk of CRC-specific mortality. Increasing consumption of marine ω-3 PUFAs after diagnosis may confer additional benefits to patients with CRC.